A New Era of Designer Babies May Be Based on Overhyped Science
By Laura Hercher,
Scientific American
| 07. 12. 2021
For better or worse, genetic testing of embryos offers a potential gateway into a new era of human control over reproduction. Couples at risk of having a child with a severe or life-limiting disease such as cystic fibrosis or Duchenne muscular dystrophy have used preimplantation genetic testing (PGT) for decades to select among embryos created through in vitro fertilization (IVF) for those that do not carry the disease-causing gene. But what new iteration of genetic testing could tempt healthy, fertile couples to reject our traditional time-tested and wildly popular process of baby making in favor of hormone shots, egg extractions and DNA analysis?
A California-based start-up called Orchid Biosciences claims it has an answer to that question. The company offers prospective parents genetic testing prior to conception to calculate risk scores estimating their own likelihood of confronting common illnesses such as heart disease, diabetes, and schizophrenia and the likelihood that they will pass such risks along to a future child. Parents-to-be can then use IVF, along with Orchid’s upcoming embryo screening package, to identify the healthiest of their embryos for... see more
Related Articles
By John Anderson, The Wall Street Journal | 05.10.2022
“Our Father,” Netflix.
A horror story presented as too much of a horror movie, “Our Father” features interviews with the offspring of fertility doctor Donald Cline, but certainly not all of them. Beginning in 1979, Dr. Cline, by his own...
By Kevin Davies, Genetic Engineering and Biotechnology News | 05.18.2022
WASHINGTON, DC — In his current role as President Biden’s acting scientific advisor, Francis Collins, MD, PhD, is dealing with a wide range of issues from semiconductor shortages to wildfires. “But my heart is in what you are all doing...
By David Jensen, The California Stem Cell Report | 05.20.2022
Photo by Giorgio Trovato on Unsplash
The directors of the $12 billion California stem cell agency are looking for a new chair who is both decisive and collaborative, passionate and inclusive. But at the top of the wish list is...
By Joanna Thompson, Scientific American | 05.18.2022
Imagine taking a genetic test that could tell you your personal risk of developing complications and dying from a particular disease, such as cancer, heart attack or even COVID. A version of such a test exists—albeit an imperfect one.
Genome-wide...